The Biology of Prostate Cancer Skeletal Metastases
The Biology of Prostate Cancer Skeletal Metastases
批准号:
10629245
负责人:
Evan T Keller
金额:
$148.08万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
未结题
起止时间:
2004-06-05 至 2025-05-31
关键词:
Abscisic AcidAddressAdoptedAnimal ModelAnimalsApoptoticBiological AssayBiologyBiometryBloodBone MarrowBone Marrow ExaminationBone TissueCellsCessation of lifeChemoresistanceClinical TrialsDevelopmentEnsureEnvironmentEvaluationExperimental Animal ModelFamilyFosteringGDF15 geneGrantGrowthHealthHistologyHumanHypoxiaImageImmunosuppressionIncidenceInjectionsInvadedLeadershipMacrophageMalignant NeoplasmsMalignant neoplasm of prostateMeasurementMetastatic Neoplasm to the BoneMetastatic Prostate CancerMethodsModelingMusNuclearOsteocytesPainPatient CarePhenotypePlayPolyploidyPredispositionPublicationsReportingResearchResearch PersonnelResource SharingRoleRunningSamplingSignal TransductionSkeletonStressSumTumor Promotionadvanced prostate canceranticancer researchbonebone cellcancer cellchemotherapyexperiencemenmouse modelmultidisciplinaryneoplastic cellnew therapeutic targetnovelpreventprogramsprostate cancer cellprostate cancer metastasisprostate cancer progressionreceptortherapeutic targettherapy resistanttumortumor growthtumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
OVERALL ABSTRACT
The common occurrence, marked debilitation and subsequent lethality of prostate cancer (PCa)
skeletal metastases has made it a major health concern. In the first fourteen years of this
program, we have addressed this important issue, resulting in a major impact on the field of
skeletal metastasis research, including promoting concepts such as crosstalk between tumor
and bone and the importance of therapeutically targeting the microenvironment, in addition to
tumor. This program has resulted in over 220-grant-related publications and set groundwork for
several clinical trials. In the current competitive renewal, we further attack this problem by
combining leading expertise in PCa research and bone biology. The central theme of this
Program is that there is crosstalk between PCa cells and the bone microenvironment that
fosters the development and progression of PCa metastasis. This crosstalk promotes the ability
of PCa cells to alter the bone microenvironment and render it fertile for tumor growth and
chemotherapeutic resistance. To expand on this theme the Program encompasses closely
interrelated hypotheses of four scientific projects supported by three cores. Project 1 explores
the novel finding that chemotherapy induces fusion of PCa cells to form multinuclear polyploid
giant cancer cells (PGCCs) that confer chemoresistance in the bone microenvironment; Project
2 examines the exciting idea that abscisic acid (ABA) induces PCa cells to adopt a phenotype
capable of existing in a dormant and chemoresistant state, with the capacity for long-term
survival and potential to develop into overt bone metastases; Project 3 explores the surprising
role that osteocytes (OCys) play in promoting PCa bone metastasis through activation of a
novel growth differentiation factor-15 (GDF15) receptor, GDFN family receptor alpha-like
precursor (GFRAL), that subsequently promotes PCa metastatic invasion and growth; Project 4
investigates the novel hypothesis that macrophage efferocytosis (engulfment) of apoptotic PCa
cells induces immunosuppressive signaling in the bone microenvironment that subsequently
enhances metastatic growth. These projects will be supported by three integral cores: Core A
(Administration) that will coordinate reporting, evaluation of progress, advisory board activities,
facilitate interactions among the projects and provide biostatistical support; Core B (Animal) will
provide mouse models and imaging and assistance with their use and Core C (Bone) will
provide expertise with bone histology processing, interpretation, and procurement of human
blood and bone marrow samples. This combination of investigators, projects and cores
provides a highly synergistic Program that is greater than the sum of its parts and will continue
to provide cutting-edge research and leadership in the field of PCa skeletal metastases.
期刊论文(249)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1158/1078-0432.ccr-10-2505
发表时间:
2011-09-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
[Shiozawa Y, Pienta KJ, Taichman RS]
通讯作者:
Taichman RS
DOI:
10.1007/s12032-016-0877-y
发表时间:
2017-03
期刊:
Medical oncology (Northwood, London, England)
影响因子:
--
作者:
[van der Toom EE, Verdone JE, Jun C, Petrisor D, Lim S, de la Rosette JJ, de Reijke TM, Gorin MA, Pienta KJ, Stoianovici D]
通讯作者:
Stoianovici D
Cells in the polyaneuploid cancer cell (PACC) state have increased metastatic potential.
多层癌细胞(PACC)状态中的细胞具有增加的转移潜力。
DOI:
10.1007/s10585-023-10216-8
发表时间:
2023-08
期刊:
CLINICAL & EXPERIMENTAL METASTASIS
影响因子:
4
作者:
[Mallin, Mikaela M. M., Kim, Nicholas, Choudhury, Mohammad Ikbal, Lee, Se Jong, An, Steven S. S., Sun, Sean X. X., Konstantopoulos, Konstantinos, Pienta, Kenneth J. J., Amend, Sarah R. R.]
通讯作者:
Amend, Sarah R. R.
DOI:
10.1016/j.bone.2011.03.687
发表时间:
2011-06-01
期刊:
BONE
影响因子:
4.1
作者:
[Li, Xin, Liao, Jinhui, Park, Serk In, Koh, Amy J., Sadler, William D., Pienta, Kenneth J., Rosol, Thomas J., McCauley, Laurie K.]
通讯作者:
McCauley, Laurie K.
DOI:
10.1002/jcb.21835
发表时间:
2008-10-01
期刊:
JOURNAL OF CELLULAR BIOCHEMISTRY
影响因子:
4
作者:
[Shiozawa, Yusuke, Havens, Aaron M., Jung, Younghun, Ziegler, Anne M., Pedersen, Elisabeth A., Wang, Jingcheng, Wang, Jianhua, Lu, Ganwei, Roodman, G. David, Loberg, Robert D., Pienta, Kenneth J., Taichman, Russell S.]
通讯作者:
Taichman, Russell S.
共 146 条
Mechanisms of Sensitivity and Resistance to the Kinase Inhibitor Cabozantinib
-
批准号:8788150
-
项目类别:
-
资助金额:$24.8万
-
财政年份:2014
-
负责人:Evan T Keller
-
依托单位:
Microfluidic PCR System for Single Cell Transcriptional Analysis
-
批准号:8446702
-
项目类别:
-
资助金额:$24.17万
-
财政年份:2013
-
负责人:Evan T Keller
-
依托单位:
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche
-
批准号:8333998
-
项目类别:
-
资助金额:$61.25万
-
财政年份:2011
-
负责人:Evan T Keller
-
依托单位:
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche
-
批准号:8713957
-
项目类别:
-
资助金额:$49.55万
-
财政年份:2011
-
负责人:Evan T Keller
-
依托单位:
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche
-
批准号:8536247
-
项目类别:
-
资助金额:$48.72万
-
财政年份:2011
-
负责人:Evan T Keller
-
依托单位:
Mechanisms of Prostate Cancer Dormancy in the Bone Marrow Niche
-
批准号:8213014
-
项目类别:
-
资助金额:$54.1万
-
财政年份:2011
-
负责人:Evan T Keller
-
依托单位:
Aging Rodent Core
-
批准号:8122845
-
项目类别:
-
资助金额:$9.34万
-
财政年份:2010
-
负责人:Evan T Keller
-
依托单位:
In vivo non-invasive 3D quantitative IVIS Spectrum molecular imaging system
-
批准号:7791805
-
项目类别:
-
资助金额:$35.99万
-
财政年份:2010
-
负责人:Evan T Keller
-
依托单位:
CORE--AGING TRANSGENIC RODENT/PATHOLOGY
-
批准号:6948014
-
项目类别:
-
资助金额:$5.8万
-
财政年份:2005
-
负责人:Evan T Keller
-
依托单位:
Prostate Cancer Metastasis Suppressor: Role of RKIP
-
批准号:6872148
-
项目类别:
-
资助金额:$25.09万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Project 3: The osteocyte-driven GDF15:GFRAL axis promotes prostate cancer bone metastasis
-
批准号:10427247
-
项目类别:
-
资助金额:$18.44万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
The Biology of Prostate Cancer Skeletal Metastases
-
批准号:8854463
-
项目类别:
-
资助金额:$151.94万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Administrative Core
-
批准号:8854464
-
项目类别:
-
资助金额:$22.37万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Administrative Core
-
批准号:9163104
-
项目类别:
-
资助金额:$33.85万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
The Biology of Prostate Cancer Skeletal Metastases
-
批准号:7282340
-
项目类别:
-
资助金额:$143.44万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Core B - Animal Core
-
批准号:10629277
-
项目类别:
-
资助金额:$35.24万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Animal Core
-
批准号:7659017
-
项目类别:
-
资助金额:$33.85万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Core A - Administrative Core
-
批准号:10427249
-
项目类别:
-
资助金额:$22.07万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Prostate Cancer Metastasis Suppressor: Role of RKIP
-
批准号:7195704
-
项目类别:
-
资助金额:$23.79万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
Prostate Cancer Metastasis Suppressor: Role of RKIP
-
批准号:6776821
-
项目类别:
-
资助金额:$25.09万
-
财政年份:2004
-
负责人:Evan T Keller
-
依托单位:
海外基金